Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Ramipril

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Ramipril is a long-acting nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor introduced for clinical use about a decade ago. Ramipril is a prodrug that undergoes de-esterification in the liver to form ramiprilat, its active metabolite. Ramipril rapidly distributes to all tissues, with the liver, kidneys and lungs showing markedly higher concentrations of the drug than the blood. After absorption from the gastrointestinal tract, rapid hydrolysis of ramipril occurs in the liver. In the therapeutic concentration range, protein binding of ramipril and ramiprilat is 73 and 56%, respectively. Ramiprilat binds to ACE with high affinity at concentrations similar to that of the enzyme and establishes equilibrium slowly.

Although ramipril is metabolised by hepatic and renal mechanisms to both a glucuronate conjugate and a diketopiperazine derivative, most of the drug is excreted in the urine as ramiprilat and the glucuronate conjugate of ramiprilat. Elimination from the body is characterised by a relatively rapid initial phase with a half-life of 7 hours and a late phase with a half-life of about 120 hours.

No clinically significant pharmacokinetic interactions between ramipril and other drugs have been reported. The drug has been generally well tolerated with the most prevalent adverse effects being dizziness (3.4%), headache (3.2%), weakness (1.9%) and nausea (1.7%).

Ramipril is an effective and well tolerated drug for the treatment of hypertension and congestive heart failure in all patients, including those with renal or hepatic dysfunction, and the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aurell M, Delin K, Herlitz H, Ljungman S, Witte PU, et al. Pharmacokinetics and pharmacodynamics of ramipril in renal failure. American Journal of Cardiology 59: 65D–69D, 1987

    Article  PubMed  CAS  Google Scholar 

  • Bainbridge AD, MacFadyen RJ, Lees KR, Reid JL. A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects. British Journal of Clinical Pharmacology 31(2): 148–153, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ball SG, Robertson JIS. Clinical pharmacology of ramipril. American Journal of Cardiology 59: 65D–69D, 1987

    Article  Google Scholar 

  • Bauer B, Lorenz H, Zahlten R. An open multicenter study to assess the long term efficacy, tolerance, and safety of the angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): S70–S74, 1989

    Article  PubMed  Google Scholar 

  • Bender N, Rangoonwala B, Rosenthal J, Vasmant D. Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor, ramipril, and their clinical implications. Clinical Physiology and Biochemistry 8 (Suppl. 1): 44–52, 1990

    PubMed  CAS  Google Scholar 

  • Boeijinga JK, Matroos AW, Van Maarschalkerweed MW, Jertich-Bastiaanse A, Breimer DD. No interaction shown between ramipril and coumarin derivatives. Current Therapeutic Research 44: 902–908, 1988

    Google Scholar 

  • Brogden RN, Todd PA, Sorkin EM. Captopril: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 36: 540–600, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bünning P. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo (3.3.0) octane-3-carboxylic acid (HOE 498 Diacid): comparison with captopril and enalaprilat. Arzneimittel-Forschung (Drug Research) 34(II): 1406–1410, 1984

    Google Scholar 

  • Debusmann ER, Pujadas JO, Lahn W, Irmisch R, Jane F, et al. Influence of renal function on the pharmacokinetics of ramipril (HOE 498). American Journal of Cardiology 59: 70D–78D, 1987

    Article  PubMed  CAS  Google Scholar 

  • De Leeuw PW, Ammerdorfer TH, Birkenhager WH. Experience with HOE 498, a long-acting converting enzyme inhibitor. Second European Meeting on Hypertension, Milan, June 9–12. Abstract no. 130, 1985

    Google Scholar 

  • Doering W, Maass L, Irmisch R, Konig E. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. American Journal of Cardiology 59: 60D–64D, 1987

    Article  PubMed  CAS  Google Scholar 

  • Eckert HG, Badian MJ, Gantz D, Kellner HM, Volz M. Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl] — L-alanyl]-(1S,3S,5S)-azabicyclo[3.3.0]octane-3-carboxylic acid (HOE 498) in rat, dog and man. Arzneimittel-Forschung 34: 1435–1477, 1984

    PubMed  CAS  Google Scholar 

  • Eckert HG, Munscher G, Oekonomopulos R, Strecker H, Urbach H, et al. A radioimmunoassay for the angiotensin converting enzyme inhibitor ramipril and its active metabolite. Arzneimittel-Forschung 35: 1251–1256, 1985

    PubMed  CAS  Google Scholar 

  • Gerckens U, Grube E, Mengden T, Sigel H, Wagner WL, et al. Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV). Journal of Cardiovascular Pharmacology 13 (Suppl. 3): 549–551, 1989

    Google Scholar 

  • Gilchrist WJ, Beard K, Manhem P, Thomas EM, Robertson JIS, et al. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients. American Journal of Cardiology 59: 28D–32D, 1987

    Article  PubMed  CAS  Google Scholar 

  • Hajdu P, Bomm M, Hack L, Keller A. Detemunation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-azabicyclo[3.3.0] octane-3-carboxylic acid (HOE 498) and its hydrolysis product in serum and urine. Arzneimittel-Forschung (Drug Research) 34(II): 1431–1439, 1984

    CAS  Google Scholar 

  • Harada A, Inenaga T, Washio M. Pharmacokinetics of ramipril in chronic renal failure. Current Therapeutic Research 44: 200–212, 1988

    Google Scholar 

  • Hosie J, Meredith P. The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension. Journal of Cardiovascular Pharmacology 18 (Suppl. 2): S125–S127, 1991

    PubMed  Google Scholar 

  • Kaneko Y, Omae T, Yoshinaga K, Iimura O, Inagaki Y, et al. Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension. American Journal of Cardiology 59: 86D–91D, 1987

    Article  PubMed  CAS  Google Scholar 

  • Kondo K, Ohashi K, Saruta T, Shimura M, Yotodera K. Tolerability, pharmacodynamics and pharmacokinetics of HOE 498 after multiple administration of 5 mg for 15 days in healthy male subjects. Japanese Pharmacology and Therapeutics 14: 339–359, 1986

    Google Scholar 

  • Manhem PJO, Ball SG, Morton JJ, Murray GD, Leckie BJ, et al. A dose response study of HOE 498, a new non-sulfhydril converting enzyme inhibitor, on blood pressure, pulse rate and the renin-angiotensin aldosterone system in normal man. British Journal of Clinical Pharmacology 20: 27–35, 1985

    Article  PubMed  CAS  Google Scholar 

  • Meisel S, Shamiss A, Verho MT, Rosenthal T. Ramipril in the treatment of severe hypertension: pharmacokinetics and clinical efficacy. Current Therapeutic Research 49(6): 1–6, 1991

    Google Scholar 

  • Metzger H, Maier L, Sitter C, Stern HO. 2-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo(3.3.0)octane-3-carboxylic acid (HOE 498) — a new and highly effective angiotensin I converting enzyme inhibitor. Arzneimittel-Forschung 34(11): 1402–2405, 1984

    PubMed  CAS  Google Scholar 

  • Meyer BH, Muller FO, Badian M, Eckert HG, Hajdu P, et al. Pharmacokinetics of ramipril in the elderly. American Journal of Cardiology 59: 33D–37D, 1987

    Article  PubMed  CAS  Google Scholar 

  • Schunkert H, Kindler J, Gassman M, Lahn W, Irmisch R, et al. Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency. European Journal of Pharmacology 37: 249–256, 1989

    Article  CAS  Google Scholar 

  • Shapiro R. Activation and inactivation of rabbit pulmonary angiotensin converting enzyme, PhD Thesis, Harvard University, Cambridge, 1983

    Google Scholar 

  • Shionoiri H, Ikeda Y, Kimura K, Miyakawa T, Kaneko Y. Pharmacodynamics and pharmacokinetics of single-dose ramipril in hypertensive patients with various degrees of renal function. Current Therapeutic Research 40: 74–85, 1986

    Google Scholar 

  • Shionoiri H, Miyakawa T, Yasuda G, Ishikawa Y, Umemura S, et al. Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension. Journal of Cardiovascular Pharmacology 10 (Suppl. 7): S145–S147, 1987

    Article  PubMed  Google Scholar 

  • Todd PA, Benfield P. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 39: 110–135, 1990

    Article  PubMed  CAS  Google Scholar 

  • Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vasmant D, Bender N. The renin-angiotensin system and ramipril, a new converting enzyme inhibitor. Journal of Cardiovascular Pharmacology 14 (Suppl. 4): S46–S52, 1989

    PubMed  CAS  Google Scholar 

  • Verho M, Malerczyk V, Grotsch H, Zenbil I. Absence of interaction between ramipril, a new ACE-inhibitor, and phenprocoumon, an anticoagulant agent. Pharmatherapeutica 5: 392–399, 1989

    PubMed  CAS  Google Scholar 

  • Witte PU, Irmisch R, Hajdu P, Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. European Journal of Clinical Pharmacology 27: 577–581, 1984

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Chaim Sheba Medical Center, The Chorley Institute of Hypertension, Tel Hashomer, Israel

    Simcha Meisel, Arie Shamiss & Talma Rosenthal

  2. Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel

    Simcha Meisel, Arie Shamiss & Talma Rosenthal

Authors
  1. Simcha Meisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arie Shamiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Talma Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meisel, S., Shamiss, A. & Rosenthal, T. Clinical Pharmacokinetics of Ramipril. Clin. Pharmacokinet. 26, 7–15 (1994). https://doi.org/10.2165/00003088-199426010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199426010-00002

Keywords

Search

Navigation